Kristi Bentler1, Shaohui Zhai2, Sara A Elsbecker3, Georgianne L Arnold4, Barbara K Burton5, Jerry Vockley4, Cynthia A Cameron2, Sally J Hiner2, Mathew J Edick2, Susan A Berry6. 1. Minnesota Department of Health, St. Paul, MN, United States. 2. Michigan Public Health Institute, Okemos, MI, United States. 3. University of Minnesota, Department of Pediatrics, Minneapolis, MN, United States. 4. Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. 5. Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, United States. 6. University of Minnesota, Department of Pediatrics, Minneapolis, MN, United States. Electronic address: berry002@umn.edu.
Abstract
INTRODUCTION: There is limited understanding of relationships between genotype, phenotype and other conditions contributing to health in neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) identified through newborn screening. METHODS: Retrospective analysis of comprehensive data from a cohort of 221 newborn-screened subjects identified as affected with MCADD in the Inborn Errors of Metabolism - Information System (IBEM-IS), a long term follow-up database of the Inborn Errors of Metabolism Collaborative, was performed. RESULTS: The average age at notification of first newborn screen results to primary care or metabolic providers was 7.45days. The average octanoylcarnitine (C8) value on first newborn screen was 11.2μmol/L (median 8.6, range 0.36-43.91). A higher C8 level correlated with an earlier first subspecialty visit. Subjects with low birth weight had significantly lower C8 values. Significantly higher C8 values were found in symptomatic newborns, in newborns with abnormal lab testing in addition to newborn screening and/or diagnostic tests, and in subjects homozygous for the c.985A>G ACADM gene mutation or compound heterozygous for the c.985A>G mutation and deletions or other known highly deleterious mutations. Subjects with neonatal symptoms, or neonatal abnormal labs, or neonatal triggers were more likely to have at least one copy of the severe c.985A>G ACADM gene mutation. C8 and genotype category were significant predictors of the likelihood of having neonatal symptoms. Neonates with select triggers were more likely to have symptoms and laboratory abnormalities. CONCLUSIONS: This collaborative study is the first in the United States to describe health associations of a large cohort of newborn-screened neonates identified as affected with MCADD. The IBEM-IS has utility as a platform to better understand the characteristics of individuals with newborn-screened conditions and their follow-up interactions with the health system.
INTRODUCTION: There is limited understanding of relationships between genotype, phenotype and other conditions contributing to health in neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) identified through newborn screening. METHODS: Retrospective analysis of comprehensive data from a cohort of 221 newborn-screened subjects identified as affected with MCADD in the Inborn Errors of Metabolism - Information System (IBEM-IS), a long term follow-up database of the Inborn Errors of Metabolism Collaborative, was performed. RESULTS: The average age at notification of first newborn screen results to primary care or metabolic providers was 7.45days. The average octanoylcarnitine (C8) value on first newborn screen was 11.2μmol/L (median 8.6, range 0.36-43.91). A higher C8 level correlated with an earlier first subspecialty visit. Subjects with low birth weight had significantly lower C8 values. Significantly higher C8 values were found in symptomatic newborns, in newborns with abnormal lab testing in addition to newborn screening and/or diagnostic tests, and in subjects homozygous for the c.985A>G ACADM gene mutation or compound heterozygous for the c.985A>G mutation and deletions or other known highly deleterious mutations. Subjects with neonatal symptoms, or neonatal abnormal labs, or neonatal triggers were more likely to have at least one copy of the severe c.985A>G ACADM gene mutation. C8 and genotype category were significant predictors of the likelihood of having neonatal symptoms. Neonates with select triggers were more likely to have symptoms and laboratory abnormalities. CONCLUSIONS: This collaborative study is the first in the United States to describe health associations of a large cohort of newborn-screened neonates identified as affected with MCADD. The IBEM-IS has utility as a platform to better understand the characteristics of individuals with newborn-screened conditions and their follow-up interactions with the health system.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Gwendolyn Gramer; Gisela Haege; Junmin Fang-Hoffmann; Georg F Hoffmann; Claus R Bartram; Katrin Hinderhofer; Peter Burgard; Martin Lindner Journal: JIMD Rep Date: 2015-05-05
Authors: Brage Storstein Andresen; Allan Meldgaard Lund; David Michael Hougaard; Ernst Christensen; Birthe Gahrn; Mette Christensen; Peter Bross; Anne Vested; Henrik Simonsen; Kristin Skogstrand; Simon Olpin; Niels Jacob Brandt; Flemming Skovby; Bent Nørgaard-Pedersen; Niels Gregersen Journal: Mol Genet Metab Date: 2012-04-04 Impact factor: 4.797
Authors: T H Zytkovicz; E F Fitzgerald; D Marsden; C A Larson; V E Shih; D M Johnson; A W Strauss; A M Comeau; R B Eaton; G F Grady Journal: Clin Chem Date: 2001-11 Impact factor: 8.327
Authors: B S Andresen; P Bross; T G Jensen; V Winter; I Knudsen; S Kølvraa; U B Jensen; L Bolund; M Duran; J J Kim Journal: Am J Hum Genet Date: 1993-09 Impact factor: 11.025
Authors: Sarah C Grünert; A Wehrle; P Villavicencio-Lorini; E Lausch; B Vetter; K O Schwab; S Tucci; U Spiekerkoetter Journal: BMC Med Genet Date: 2015-07-30 Impact factor: 2.103